Table 3.

Baseline characteristics of prostate cancer group.

Prostate cancer group
	N (132)	Age (years) Mean (range)	PSA serum level (ng/mL) Mean (range)	Clinical stage	Pathological Gleason Score	Pathological stage
Low risk PCa	23	61 (52–74)	7.26 (3–17.5)	T1c	3 + 3	pT2a–pT2c
Intermediate risk PCa	47	65 (50–78)	7.32 (1.5–29)	T1c	3 + 4	pT2a–pT3
High risk PCa	48	63 (50–77)	10.8 (0.60–62)	T1c–T3	> 3 + 4	pT2a–pT3b
PCa at prostate biopsy	7	59 (46–75)	5.4 (3.2–9.0)	T1c	3 + 3; 3 + 4; 4 + 3
PCa biochemical relapse	3	69 (61–79)	1 (0.6–2.1)
Metastatic PCa	4	71 (66–84)	12 (10–78)